Roche sees a slight dip in Q1 as biosim­i­lars keep bit­ing in­to block­buster on­col­o­gy tri­o's sales

With Roche fac­ing a fast de­cline for its on­col­o­gy block­buster trio amid a biosim­i­lar on­slaught, the drug gi­ant is look­ing any­where it can for a pick-me-up. That boost could come from Covid-19 di­ag­nos­tics, the drug­mak­er said in a first-quar­ter up­date — but will it be enough?

The test­ing di­vi­sion saw a marked 55% in­crease in sales, Roche ex­ec­u­tives said on an earn­ings call with an­a­lysts Wednes­day, off­set­ting a slump­ing phar­ma­ceu­ti­cals sec­tor which pulled in 9% less than the same three-month pe­ri­od in 2020. In­clud­ed in that in­crease is Roche’s rapid Covid-19 anti­gen test, as well as re­search for its re­al-time PCR test to help mon­i­tor coro­n­avirus mu­ta­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER